Study of the Usefulness of Dosage and Administration of the Anti-MRSA Drug Arbekacin Sulfate (ABK) Set at a Peak Blood Concentration of 15-20 g/L - Study of the Usefulness of Dosage and Administration of ABK Set at a Peak Blood Concentration of 15-20 g/

Kitasato University Research Center for Anti-infection Drugs0 个研究点目标入组 100 人开始时间: 2010年3月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have received any other anti-MRSA drug (VCM, TEIC, LZD) 2) Patients with reduced renal function (creatinine clearance 30 ml/min/1.73 m2 or less) 3) Patients who are pregnant or might be pregnant 4) Patients who themselves or whose blood relatives have hearing loss caused by an aminoglycoside antibiotic, or other form of hearing loss 5) Patients on any form of dialysis (hemodialysis: HD; continuous ambulatory peritoneal dialysis: CAPD; continuous hemodiafiltration, CHDF) 6) Patients whom the physician in charge judges to be unsuitable for any other reason

发起方

Kitasato University Research Center for Anti-infection Drugs